Immunocore

KIMMTRAK

Manufacturer:

Immunocore

Kimmtrak HCPCS:

J9274

HCPCS Code Descriptor:

Injection, tebentafusp-tebn, 1 microgram

Category:

J Code

Kimmtrak NDCs:

80446-0401-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Kimmtrak:

KIMMTRAK is an Oncology drug manufactured by Immunocore and administered via the Intravenous route of administration. The J Code: J9274 is aligned to the drug KIMMTRAK.

Kimmtrak is a type of monoclonal antibody and is used to treat certain types of cancer. Kimmtrak works by slowing down preventing the growth of cancer cells. Kimmtrak is administered via a 15-to-20-minute intravenous infusion. Kimmtrak is a branded drug manufactured by Immunocore Commercial. From July 2022 to September 2022, Kimmtrak was assigned to the temporary C Code: C9095. Beginning in October 2022, Kimmtrak received the J Code: J9274. Patient assistance programs for this medication can be found through Immunocore.

ACCESS PRICING AND MORE BY REGISTERING

J9274 Added Date:

October 1, 2022

J9274 Effective Date:

October 1, 2022

J9274 Termination Date:

HCPCS Active

Kimmtrak billing and coding information can be found through Immunocore at the link below:
Kimmtrak patient assistance information can be found through Kimmtrack Connect at the URL: https://www.kimmtrakconnect.com/financial-assistance/
KIMMTRAK prescribing information can be found at the link below:
Information regarding KIMMTRAK’s side effects can be found at MedlinePlus